ストックスクリーナーアプリを入手
0.663
0.32%
0.0021
プレマーケット:
.66
-0.003
-0.45%
前日終値:
$0.6609
開ける：
$0.67
24時間の取引高:
382.22K
Relative Volume:
1.13
時価総額：
$47.08M
収益：
$391.70K
当期純損益:
$-52.34M
株価収益率:
-0.884
EPS:
-0.75
ネットキャッシュフロー:
$-45.92M
1週間 パフォーマンス:
-8.92%
1か月 パフォーマンス:
-31.21%
6か月 パフォーマンス:
-30.94%
1年 パフォーマンス:
-82.08%
1日の値動き範囲:
$0.65
$0.7186
1週間の範囲:
$0.65
$0.8079
52週間の値動き範囲:
$0.65
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.663 | 47.08M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
Ovid Therapeutics (NASDAQ:OVID) Upgraded by Oppenheimer to Outperform Rating - MarketBeat
Oppenheimer raises Ovid stock rating, sets $4 price target - MSN
Ovid Therapeutics stock hits 52-week low at $0.68 amid downturn - MSN
Ovid upgraded to outperform by Oppenheimer, OV329 cited - MSN
Ovid therapeutics president and COO acquires $4,971 in stock - MSN
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’ - Yahoo Finance
Oppenheimer Upgrades Ovid Therapeutics to Outperform From Perform, $4 Price Target - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Barclays PLC Acquires 63,702 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Insider Activity Raises Eyebrows! Key Moves at Ovid Therapeutics! - Jomfruland.net
Ovid Therapeutics Insider Ups Holding During Year - Yahoo Finance
Short Interest in Ovid Therapeutics Inc. (NASDAQ:OVID) Decreases By 27.0% - MarketBeat
Jane Street Group LLC Has $45,000 Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - Defense World
Ovid’s Gameplan: Flicking The Master Switch In Neurology - News & Insights
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Geode Capital Management LLC Acquires 14,816 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
TG Therapeutics (NASDAQ:TGTX) Raised to Hold at StockNews.com - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Acquired by Barclays PLC - Defense World
Fragile X Syndrome Market Expected to rise, 2034 | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia - Barchart
Ovid Therapeutics Inc (NASDAQ: OVID) Drops -2.44 Percent In Recent Trading, What Questions Do You Have? - Stocks Register
Ovid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short Interest - MarketBeat
Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935 - Reuters
Fmr LLC Acquires 47,723 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - MarketBeat
Verition Fund Management LLC Makes New Investment in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
3 US Penny Stocks With Market Caps Over $20M - Simply Wall St
Convergent Therapeutics Appoints Barbara Duncan to Board of Directors - citybiz
HC Wainwright Has Bullish Estimate for OVID FY2024 Earnings - MarketBeat
HC Wainwright Has Strong Forecast for OVID FY2024 Earnings - Defense World
KCC2 activation nears inflection point - BioCentury
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Ovid Therapeutics to Present Multiple Posters Supporting - GlobeNewswire
Ovid Therapeutics Unveils Breakthrough Epilepsy Treatment Data at Major Conference | OVID Stock News - StockTitan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus PT from Analysts - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Analysts - MarketBeat
B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Equities Analysts Offer Predictions for OVID FY2024 Earnings - MarketBeat
Fragile X Syndrome (Fxs) Treatment Market Growth Overview - openPR
Wedbush Forecasts Weaker Earnings for Ovid Therapeutics - Defense World
Equities Analysts Issue Forecasts for OVID FY2024 Earnings - Defense World
William Blair Has Positive Outlook for OVID FY2024 Earnings - MarketBeat
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
4.02%
0.32%
大文字化:
|
ボリューム (24 時間):